Financials data is unavailable for this security.
View more
Year on year Eterna Therapeutics Inc has grown net income from a loss of -24.58m to a smaller loss of -21.67m primarily through revenue growth (0.00 to 68.00k). For while the costs associated with cost of goods, selling, general and administrative and debt all increased as a percentage of sales , the -- growth in revenues contributed enough to still see net income improve.
| Gross margin | 72.91% |
|---|---|
| Net profit margin | -7,513.88% |
| Operating margin | -6,886.62% |
| Return on assets | -149.86% |
|---|---|
| Return on equity | -- |
| Return on investment | -222.51% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Eterna Therapeutics Inc fell by 3.87m. Cash Flow from Financing totalled 16.56m or 24,347.06% of revenues. In addition the company used 20.41m for operations while cash used for investing totalled 19.00k.
| Cash flow per share | -8.28 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | -8.39 |
|---|---|
| Tangible book value per share | -8.77 |
More ▼
Balance sheet in USDView more
| Current ratio | 0.4753 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
